The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1427
ISSUE1427
October 14, 2013
Brimonidine Gel (Mirvaso) for Rosacea
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Brimonidine Gel (Mirvaso) for Rosacea
October 14, 2013 (Issue: 1427)
The FDA has approved the selective alpha2-adrenergic
receptor agonist brimonidine as a 0.33% gel
(Mirvaso – Galderma) for topical treatment of adults
with persistent facial erythema of rosacea. Brimonidine
is also available in ophthalmic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.